Copy
***Disclaimer***
LISAvienna Newsletter February 2018 – Get Connected
Is this email not displaying correctly?
View it in your browser

Newsletter February 2018

Dear reader,

Vienna is a great place for starting up innovative companies. We invite you to read our contribution to the ABA blog focusing on 360° support for life sciences and hope you like the news review we have included in this newsletter.

Currently, loads of additional news and event tips are piling up in our inbox, which is great! However, we need help uploading them onto our webpage. Please spread the word and promote our job offer for students in the life sciencees.

Would you like your medical biotech start-up to hook up to big pharma? In addition to joining partnering events, there are more informal settings that will allow you to benefit from key know-how on R&D, business development and much more. For example, senior professionals from Boehringer Ingelheim will be available for one-on-one discussions once again on April 19, 2018 at the Vienna BioCenter. Please submit your BI Office Hours request early on to land one of the coveted meeting slots.

Have a great day and enjoy reading,
LISAvienna

BIOTECHNOLOGY & PHARMA

APEIRON Biologics and Evotec achieve first milestone in € 200 million immuno-oncology alliance with Sanofi
The strategic collaboration on small molecule leads and targets for next-generation therapies in immuno-oncology was set up in 2015 by APEIRON Biologics, Evotec, and Sanofi. Now, the advancement of an undisclosed, new, small molecule into late-stage pre-clinical development has triggered a milestone payment. The € 3 million will be split equally between the two biotech companies.
Arsanis announces closing of Initial Public Offering
Arsanis, Inc. (NASDAQ:ASNS) is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases. The gross proceeds to Arsanis from the offering were $46.0 million, before deducting underwriting discounts and commissions in addition to other offering expenses.
Biomay and MedUni Vienna: First recombinant vaccine in the world developed against grass pollen allergy
Immunotherapy with BM32 is based on an innovative recombinant peptide-carrier technology that was developed at the Christian Doppler Laboratory for Allergy Research under the direction of Rudolf Valenta. Recently, promising Phase II b results with 180 patients in 11 European centers have been published.
Themis raises € 10 million in series C financing
The GHIF-led investment will be used to advance Themis’s clinical and pre-clinical vaccine development programs, including its most advanced vaccine against chikungunya virus, on which the company recently reported positive Phase 2 results.
FDA grants Orphan Drug Designation to Zytoprotec's unique dialysis fluid for the treatment of patients with end-stage renal disease
Zytoprotec is currently preparing a pivotal Phase III clinical trial with PD-protec® in 300 patients in Europe and the United States. The orphan designation will provide Zytoprotec with several development incentives including market exclusivity for up to seven years upon FDA approval.

MEDICAL DEVICES, IVD & HEALTH CARE

New: Austrian BioImaging Industry Board (ABIB)
BioImaging Austria/CMI (Correlated Multimodal Imaging Node Austria) has established an Industry Board to connect all stakeholders interested in bioimaging and image processing in Austria. Concerted efforts and activities among life scientists, imaging scientists, computer experts, and the industry will foster multimodal imaging and drive innovation.
Grapevine World to revolutionize healthcare: The first GRAPE Tokens are available now!
Grapevine World is breaking data barriers and building a new health economy to improve healthcare worldwide. The decentralized, borderless ecosystem for the seamless exchange of health data in a standardized, secure manner offers a 50% discount in a pre-round to the ICO in Q2/2018.
ImageBiopsy Lab collaborates with Image Analysis Group
New therapeutic approaches such as stem cell and gene therapy are driving the need for a standardized, objective and reproducible assessment of X-ray data. ImageBiopsy Lab and Image Analysis Group (IAG) have joined forces to integrate machine learning into clinical research on osteoarthritis (OA).
SzeleSTIM to be granted H2020 phase 1 SME support
SzeleSTIM is focusing on wearable bio-electronic devices for Auricular Vagus Nerve Stimulation, allowing minimally invasive and non-pharmacological pain therapy adapted to the individual patient. The new grant will contribute to disrupting the global electroceutical market.
TissueGnostics significantly expands its operations in the Far East
The new office in Hong Kong serves 14 countries in the Asia-Pacific region and collaborates with distributors in six additional countries and regions. This will boost high content and/or high throughput scanning and analysis of a broad range of microscopy samples in the Far East.

ACADEMIC News

GMI to publish landmark study on an extracellular network map
MedUni Vienna to coordinate the EU-funded PECUNIA research program on standardized costing and outcome measures for optimized national healthcare provision within the EU
St. Anna Kinderkrebsforschung to start the liquid biopsy-based project “VISIOMICS” for the early prognosis of relapses in neuroblastoma patients
TU Wien: Allan Hanbury becomes the endowed professor to teach data intelligence
Uni Vienna: New approach in immune therapy to prevent tumor growth
Read more news at www.lisavienna.at.

LISAvienna UPDATE

Our news

Life Sciences Survey 2018 about to start
On behalf of BMDW, the Life Science Austria experts at aws have commissioned BIOCOM to create a new survey on life sciences in Austria. Please fill in the online form that you will receive in the next few weeks so that robust data and up-to-date input for the Austrian Life Sciences Directory can be made available by this fall!
Moreover, a new Vienna Life Science Report will be generated from this survey and selected profiles will also have the chance to be displayed at the Vienna Business Agency technology platform.

Boehringer Ingelheim Office Hours in Vienna on April 19, 2018
In collaboration with LISAvienna, Boehringer Ingelheim invites innovative biomedical start-ups and entrepreneurs to join the next BI Office Hours at the Vienna BioCenter. This is a great opportunity to benefit from BI’s science and business know-how. Please submit your meeting request by March 25, 2018 at the latest.
Meet LISAvienna

HIMSS 2018
Las Vegas, March 5-9, 2018

BIO-Europe Spring 2018
Amsterdam, March 12-14, 2018
Register as soon as possible!

MT-CONNECT and MedTech Summit 2018
Nuremburg, April 11-12, 2018

BioTrinity 2018
London, April 23-25, 2018

conhIT - Connecting Healthcare IT
Berlin, April 25-27, 2018

Bio€quity Europe
Ghent, May 14-16, 2018

HIMSS Europe 18 & Heath 2.0 Conference
Sitges, Barcelona, May 27-29, 2018

This list is not exhaustive and we reserve the right to make changes.
Latest Publication

Our media partner Chemiereport is featuring young life sciences start-ups in Vienna. Enjoy the reading!

More publications are available at www.lisavienna.at

FUNDING and SUPPORT

Vienna Business Agency: FemPower IT 2018
Supports R&D projects in the IT sector under female management, demonstrating extensive female participation or incorporating gender mainstreaming
Max. funding amount: €500,000 per project; Bonus for women: €10,000
Deadline for submitting proposals: April 17, 2018

Vienna Business Agency: Call for Exhibits for the Vienna Research Festival
The Vienna Research Festival will take place from September 14-16, 2018 and for additional nine days, a special program for school classes will be offered. This will be a great opportunity to introduce your R&D to some 10,000 participants. Please submit your proposal for an interactive display by March 9, 2018.

OPEN CALLS and DEADLINES

March 9, 2018: Vienna Business Agency – Exhibits for the Vienna Research Festival
March 15, 2018: Vienna Business Agency - Shared Facilities
March 30, 2018: FFG - COIN Networks
April 12, 2018: WWTF – Cognitive Sciences Call 2018
April 17, 2018: Vienna Business Agency – FemPower IT 2018

If you would like to keep up with international funding opportunities, especially those at the EU level, you are invited to register at lifesciences.europa@ffg.at to enjoy a free mailing service. The most recent update is available here.

Find additional deadlines at www.lisavienna.at

EVENTS in Vienna

FFG: Funding opportunities for start-ups, innovative SME and large companies

March 5, 2018, FFG, Sensengasse 1, 1090 Vienna
Please register in gold time.

Microsymposium on Small RNA Biology

June 18-20, 2018, Vienna BioCenter, Campus-Vienna-Biocenter 1, 1030 Vienna
Deadline for the PhD workshop: May 4, 2018

World Congress Immuno-Oncology 2018

June 25-26, 2018, Austria Trend Hotel Savoyen Vienna, Rennweg 16, 1030 Vienna
Please note the deadline for abstract submission: April 2, 2018
For more events be invited to www.lisavienna.at.
Your news placed here: Vienna-based organizations are invited to e-mail news and press releases to news@LISAvienna.at to contribute to LISAvienna's digital and print media.

Stay updated: Follow us on Twitter and LinkedIn and recommend our newsletter to colleagues and friends.
Copyright © LISAvienna 2018, All rights reserved.

Our mailing address is: office@LISAvienna.at

LISAvienna is a joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry for Digital, Business and Enterprise and the City of Vienna, LISAvienna contributes to the advancement of life sciences in Vienna.

unsubscribe from this list  |  update subscription preferences